Usefulness of plasma matrix metalloproteinase-9 level in predicting future coronary revascularization in patients after acute myocardial infarction

Coronary Artery Disease

Volumn 24, Issue 1, 2013, Pages 23-28

  Wang, Ko Fan ^a,d   Huang, Po Hsun ^a,c,d   Chiang, Chia Hung ^a,d   Hsu, Chien Yi ^a,d   Leu, Hsin Bang ^a,c,d   Chen, Jaw Wen ^a,b,d   Lin, Shing Jong ^a,b,c,d  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b Department of Medical Research and Education ^*  (Taiwan)

^c Institute of Clinical Medicine   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

coronary artery disease; coronary revascularization; matrix metalloproteinases

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE A; GELATINASE B; GLUCOSE; HEPARIN COFACTOR II; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRITE; TRIACYLGLYCEROL; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY BYPASS GRAFT; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL, LDL; CORONARY ARTERY BYPASS; FEMALE; HUMANS; INFLAMMATION MEDIATORS; KAPLAN-MEIER ESTIMATE; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84871739263     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0b013e32835aab4a     Document Type: Article

References (19)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-126.
2. Libby P. Inflammation in atherosclerosis. Nature 2002; 420:868-874.
3. Arroyo-Espliguero R, Avanzas P, Cosin-Sales J, Aldama G, Pizzi C, Kaski JC. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J 2004; 25:401-408.
4. Tanindi A, Sahinarslan A, Elbeg S, Cemri M. Relationship between MMP-1, MMP-9, TIMP-1, IL-6 and risk factors, clinical presentation, extent and severity of atherosclerotic coronary artery disease. Open Cardiovasc Med J 2011; 5:110-116.
5. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98:731-733.
6. Di'ez J. Emerging role of matrix metalloproteinases in the pathophysiology of cardiac diseases. Eur J Clin Invest 2002; 32:291-294.
7. Gross J, Lapiere CM. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci USA 1962; 48:1014-1022.
8. Bigg HF, Rowan AD, Barker MD, Cawston TE. Activity of matrix metalloproteinase-9 against native collagen types I and III. FEBS J 2007; 274:1246-1255.
9. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94:2493-2503.
10. Tan J, Hua Q, Gao J, Fan ZX. Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction. Clin Cardiol 2008; 31:413-418.
11. Zeng B, Prasan A, Fung KC, Solanki V, Bruce D, Freedman SB, et al. Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Intern Med J 2005; 35: 331-335.
12. Brunner S, Kim JO, Methe H. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14 + monocytes to progression of coronary artery disease. Am J Cardiol 2010; 105:429-434.
13. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26:5-20.
14. Huang PH, Lu TM, Wu TC, Lin FY, Chen YH, Chen JW, et al. Usefulness of combined high-sensitive C-reactive protein and N-terminal-probrain natriuretic peptide for predicting cardiovascular events in patients with suspected coronary artery disease. Coron Artery Dis 2008; 19: 187-193.
15. Sundstro?m J, Vasan RS. Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events. Curr Opin Lipidol 2006; 17:45-53.
16. Kalela A, Koivu TA, Sisto T, Kanervisto J, Ho? yhtya? M, Sillanaukee P, et al. Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease. Scand J Clin Lab Invest 2002; 62: 337-342.
17. Zouridakis E, Avanzas P, Arroyo-Espliguero R, Fredericks S, Kaski JC. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 2004; 110:1747-1753.
18. Ye ZX, Leu HB, Wu TC, Lin SJ, Chen JW. Baseline serum matrix metalloproteinase-9 level predicts long-term prognosis after coronary revascularizations in stable coronary artery disease. Clin Biochem 2008; 41:292-298.
19. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107:1579-1585.